328 related articles for article (PubMed ID: 31258092)
1. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
[TBL] [Abstract][Full Text] [Related]
2. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
Hitge R; Smit S; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
5. Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
Lefin R; Petzer A; Petzer JP
Bioorg Med Chem; 2022 Jan; 54():116558. PubMed ID: 34915314
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of 2-benzylidene-1-tetralone Derivatives for Monoamine Oxidase Inhibitory Activity.
Amakali KT; Legoabe LJ; Petzer A; Petzer JP
Cent Nerv Syst Agents Med Chem; 2018; 18(2):136-149. PubMed ID: 29714148
[TBL] [Abstract][Full Text] [Related]
7. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase and monoamine oxidase B inhibitory activities of Australian bee pollen.
Watanabe C; Yanagihara A; Miyata R; Mitsui T; Honda C; Fujinami D; Kumazawa S
Biosci Biotechnol Biochem; 2024 May; 88(6):665-670. PubMed ID: 38561637
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
Finberg JPM
J Neural Transm (Vienna); 2019 Apr; 126(4):433-448. PubMed ID: 30386930
[TBL] [Abstract][Full Text] [Related]
10. Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor.
Chavarria D; Benfeito S; Soares P; Lima C; Garrido J; Serrão P; Soares-da-Silva P; Remião F; Oliveira PJ; Borges F
Eur J Med Chem; 2022 Dec; 243():114740. PubMed ID: 36116233
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.
de Beer J; Petzer JP; Lourens ACU; Petzer A
Mol Divers; 2021 May; 25(2):753-762. PubMed ID: 32108308
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site.
Tripathi RKP; M Sasi V; Gupta SK; Krishnamurthy S; Ayyannan SR
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):37-57. PubMed ID: 29098902
[TBL] [Abstract][Full Text] [Related]
14. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.
Mazumder MK; Borah A; Choudhury S
Med Hypotheses; 2020 Apr; 137():109544. PubMed ID: 31954292
[TBL] [Abstract][Full Text] [Related]
16. The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat.
Odlind C; Reenilä I; Männistö PT; Ekblom J; Hansell P
Pflugers Arch; 2001 Jul; 442(4):505-10. PubMed ID: 11510881
[TBL] [Abstract][Full Text] [Related]
17. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
18. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Singh A; Naidu PS; Kulkarni SK
Pharmacology; 2003 Jun; 68(2):81-8. PubMed ID: 12711835
[TBL] [Abstract][Full Text] [Related]
19. Role of chronic inhibition of dopamine-metabolizing enzymes in the regulation of renal sodium and phosphate excretion in the rat remnant kidney.
Sampaio-Maia B; Moreira-Rodrigues M; Pestana M
Nephron Physiol; 2006; 103(1):p14-24. PubMed ID: 16352914
[TBL] [Abstract][Full Text] [Related]
20. Label-free LC-HRMS-based enzymatic activity assay for the detection of DDC, MAO and COMT inhibitors.
Harfouche A; Alata W; Leblanc K; Heslaut G; Figadère B; Maciuk A
J Pharm Biomed Anal; 2022 Apr; 212():114598. PubMed ID: 35152005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
